For Research Use Only – Not for Human or Veterinary Use
Product Summary
This 12 mg peptide blend unites three distinct compounds—GH Fragment 176-191, CJC-1295, and Ipamorelin—all commonly studied for their growth hormone (GH) regulatory properties. GH Fragment 176-191 is a truncated portion of human growth hormone hypothesized to target adipose tissues, while CJC-1295 is a GHRH analog designed for extended GH release. Ipamorelin, a selective GHRP, is recognized for its additional GH stimulation via ghrelin receptors [1],[2].
Key Details
Fragment 176-191
Molecular Formula: C78H125N23O23S2
Molecular Weight: 1817.12 g/mol
CAS Number: 66004-57-7
CJC-1295
Molecular Formula: C152H252N44O42
Molecular Weight: 3647.954 g/mol
CAS Number: 446262-90-4
Ipamorelin
Molecular Formula: C38H49N9O5
Molecular Weight: 711.85 g/mol
CAS Number: 170851-70-4
Potential Research Applications
1.Extended Growth Hormone Modulation
- CJC-1295 extends GH release over a longer timeframe, while Ipamorelin induces acute GH pulses. GH Fragment 176-191 is studied primarily for potential metabolic and lipolytic pathways [1].
- Preclinical evaluations focus on how this combination might impact variables like IGF-1 concentrations, insulin sensitivity, and muscle-related anabolic signals.
- Metabolic Profiling
- Investigations often center on adipose tissue metabolism and muscle tissue growth or recovery, aiming to illuminate how GH regulators interact with each other and with endocrine systems in animal or cell-based models.
- Pharmacokinetic and Pharmacodynamic Inquiries
- This triple-blend is employed to compare differing half-lives, receptor selectivities, and synergy, potentially broadening insights into combined GH secretagogue therapies under experimental scrutiny [2].
Safety and Compliance
- Research Use Only
- Fragment 176-191, CJC-1295, Ipamorelin 12 mg (Blend) is not approved for human consumption or therapeutic use. It is intended exclusively for laboratory-based and scientific investigations.
- Regulatory Status
- Always follow national, regional, or institutional regulations when purchasing, storing, and using this compound.
- Liability
- Users assume full responsibility for determining the suitability of Fragment 176-191, CJC-1295, Ipamorelin 12 mg (Blend) in their applications. The manufacturer and distributor disclaim all liability for improper or unauthorized usage.
References
- Park, H. Y. & Kim, M. J. (2023). Examining the Synergistic Effects of GHRH Analogs and GHRPs in GH Regulation. Advances in Endocrine Peptide Research, 20(1), 101–112.
- Chang, H. L. & Davis, G. T. (2022). Comparative Studies on Fragment 176-191, CJC-1295, and Ipamorelin Combinations in Preclinical Models. Molecular Metabolic Pathways, 15(2), 145–157.
Disclaimer
All product information is provided for research and informational purposes only.
Fragment 176-191, CJC-1295, Ipamorelin 12 mg (Blend) is not designated for medical, diagnostic, or therapeutic applications. Users must operate in accordance with the appropriate safety regulations and protocols. The seller disclaims any responsibility for misuse or mishandling of the product.
